financetom
Business
financetom
/
Business
/
Update: Taseko Mines Books Lower Copper and Molybdenum Production YoY in Q2
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Taseko Mines Books Lower Copper and Molybdenum Production YoY in Q2
Jul 15, 2024 8:54 AM

11:37 AM EDT, 07/15/2024 (MT Newswires) -- Taseko Mines ( TGB ) was last seen down 2.6% as the company on Monday reported a year-over-year decline in second-quarter copper and molybdenum production from its Gibraltar mine in British Columbia and lowered its guidance range.

Taseko produced 20 million pounds of copper and 185,000 pounds of molybdenum, in the period, dropping from 28 million pounds of copper and 230,000 pounds of molybdenum, in the year-prior quarter.

This is in line with National Bank of Canada's estimates of 21.3 million pounds of copper and 181,000 pounds of molybdenum, according to a Monday note.

Taseko now expects full-year 2024 copper production to be in the range of 110-million to 115-million pounds, compared to the original guidance of 115 million pounds.

The miner attributed the lower output to mill downtime for the relocation of the in-pit crusher, concurrent maintenance activities in concentrator #1, and a strike by the mine's unionized workforce in June.

Taseko said it completed the in-pit crusher move in late May but the final installation work and other mill maintenance was interrupted by the 18-day strike in June. Work resumed following the strike and is now completed.

Meanwhile, Taseko said concentrator #1 has restarted and is in the process of ramping up to full capacity.

Taseko added that concentrator #2 has been running consistently and at improved throughput rates since the repair work in January. The company expects to receive insurance proceeds of US$22 million in the third quarter.

"Production in the second half of 2024 is expected to be stronger with the major project and maintenance work in both concentrators completed," chief executive Stuart McDonald said.

Taseko maintained its sector-perform rating and $4.25 price target at National Bank of Canada following the news.

Taseko's shares were last seen down $0.09 to $3.33 on the Toronto Stock Exchange.

Price: 3.33, Change: -0.09, Percent Change: -2.63

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Healthcare Services Q2 Loss Widens, Revenue Rises
Healthcare Services Q2 Loss Widens, Revenue Rises
Jul 23, 2025
07:34 AM EDT, 07/23/2025 (MT Newswires) -- Healthcare Services Group ( HCSG ) reported a Q2 loss Wednesday of $0.44 per diluted share, wider than a loss of $0.02 a year earlier. Two analysts surveyed by FactSet expected earnings of $0.21 per share. Revenue for the three months ended June 30 was $458.5 million, up from $426.3 million last year....
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Jul 23, 2025
Abivax SA ( ABVX ) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials for oral obefazimod (ABX464) in adult patients with moderately to severely active ulcerative colitis. The Paris-based company achieved a significant breakthrough with its experimental treatment, which...
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Jul 23, 2025
07:31 AM EDT, 07/23/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Wednesday the US Food and Drug Administration has granted breakthrough device designation for the company's DecisionDx-Melanoma test. DecisionDx-Melanoma is a gene expression profile test that provides results to guide risk-aligned management decisions for patients diagnosed with stage I to III cutaneous melanoma, a type of skin cancer....
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved